Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ORITAVANCIN vs OSIMERTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ORITAVANCIN vs OSIMERTINIB: Safety Overview

Metric ORITAVANCIN OSIMERTINIB
Total FAERS Reports 884 27,750
Deaths Reported 29 12,456
Death Rate 3.3% 44.9%
Hospitalizations 157 5,277
Average Patient Age 55.9 yrs 68.2 yrs
% Female Patients 52.2% 66.0%
FDA Approval Date N/A Nov 13, 2015
Manufacturer Melinta Therapeutics, LLC AstraZeneca Pharmaceuticals LP
Route INTRAVENOUS ORAL
Marketing Status N/A Prescription